Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.


Kids maintain HIV suppression on low-dose, quad-combo pill

Jairia Dela Cruz
07 Aug 2020

At a lower dose, the single-pill drug that combines elvitegravir (EVG), cobicistat, emtricitabine, and tenofovir alafenamide (TAF) has an acceptable safety profile and maintains virological suppression in HIV-infected children, according to the results of a single-arm, open label trial.

Safety and efficacy of the low-dose quad pill in young children are consistent with its full‐strength efficacy in older populations, the investigators said. Furthermore, drug exposures in the paediatric population appear to be within range of adult historical data.

Presented at the virtual meeting of the 23rd International AIDS Conference, the trial enrolled 27 children with HIV‐1 RNA <50 copies/mL for ≥6 months and CD4 count of ≥200 cells/μL. The median age was 6 years (range, 3–9), and the median weight was 19 kg (range, 15–24). Sixty-three percent of the children were girls, and 89 percent were black. The median CD4 count was 1,061 cells/μL (range, 383–2,401).

All children were given the quad-combo drug once daily, with each tablet containing 90-mg EVG, 90-mg cobicistat, 120-mg emtricitabine, and 6-mg TAF. Over 24 weeks of treatment, six patients developed upper respiratory tract infection (22 percent), five had cough (19 percent), and four showed decreased appetite (15 percent). All adverse events were mild to moderate in severity, and none of the children discontinued treatment due to these events. [AIDS 2020, abstract OABLB0101]

HIV remained suppressed in all children at week 16 and in 10 of 11 (91 percent) at week 24. One patient had HIV‐1 RNA between 200 to <400 copies/mL. CD4 count decreased by a mean of 95 cells/mL (0.3 percent) from baseline at the final follow-up.

Pharmacokinetic analysis revealed that compared with adults treated with the standard-dose combination (150-mg EVG, 150-mg cobicistat, 200-mg emtricitabine, and 10-mg TAF), total exposure levels to both low-dose EVG and TAF (as indicated by area under the curves) in children were modestly higher—less than twofold. Exposures of all analytes stayed within range of historical data.

Swallowability, acceptability, and palatability of the low-dose quad-combo drug were favourable at all timepoints assessed for most children.

The standard-dose quad-combo pill is approved as a complete antiretroviral therapy (ART) regimen in children aged ≥6 years weighing ≥25 kg. It can be used in ART-naïve children and to replace the current ART regimen in those who have been virologically suppressed. The drug is said to carry a lower risk of bone and renal toxicity as compared with regimens containing tenofovir disoproxil fumarate. [https://aidsinfo.nih.gov/contentfiles/lvguidelines/glchunk/glchunk_279.pdf]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 2 days ago
In patients with heart failure with reduced ejection fraction (HFrEF) receiving angiotensin-converting-enzyme (ACE) inhibitors, high dosing confers benefits for the risk of death or hospitalization that are similar to that obtained with lower dosing, according to a systematic review and meta-analysis.
11 Sep 2020
Men who use calcium channel blockers (CCBs) are at risk of developing prostate cancer, and the risk increases with the duration of CCB exposure, according to the results of a systematic review and meta-analysis.
06 Sep 2020
Type 2 diabetes mellitus patients taking proton pump inhibitors (PPIs) are at a higher risk of sustaining hip fractures, a recent study has found.
4 days ago
Osteoarthritis (OA) is the most common condition affecting the joints. Dr Lee Eu Jin, an Orthopaedic Surgeon from Liberty Orthopaedic Clinic at Mount Elizabeth Medical Centre, Singapore, shares his insights with Pearl Toh on how to manage OA in the primary care setting.